Year All20242023 Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation February 16, 2024 PDF Version Read More Clarion Clinics Open for Psychedelic-Assisted Treatments February 1, 2024 PDF Version Read More Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis January 24, 2024 PDF Version Read More Incannex Completes Dosing and Therapy in Phase 2 "PsiGAD" Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences January 18, 2024 PDF Version Read More Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea January 17, 2024 PDF Version Read More ASX Announcements
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation February 16, 2024 PDF Version Read More
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis January 24, 2024 PDF Version Read More
Incannex Completes Dosing and Therapy in Phase 2 "PsiGAD" Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences January 18, 2024 PDF Version Read More
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea January 17, 2024 PDF Version Read More
